Ross, CA, Tabrizi, SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol
2011; 10: 83–98.
Kozauer, N, Katz, R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med
2013; 368: 1169–71.
Borsook, D, Becerra, L, Fava, M. Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry
2013; 3: e282.
Tabrizi, SJ, Scahill, RI, Durr, A, Roos, RA, Leavitt, BR, Jones, R, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol
2011; 10: 31–42.
Aylward, EH, Codori, AM, Rosenblatt, A, Sherr, M, Brandt, J, Stine, OC, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord
2000; 15: 552–60.
Aylward, EH, Nopoulos, PC, Ross, CA, Langbehn, DR, Pierson, RK, Mills, JA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry
2011; 82: 405–10.
Henley, SMD, Wild, EJ, Hobbs, NZ, Frost, C, MacManus, DG, Barker, RA, et al. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord
2009; 24: 932–6.
Hobbs, NZ, Henley, SMD, Wild, EJ, Leung, KK, Frost, C, Barker, RA, et al. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease. NeuroImage
2009; 47: 1659–65.
Hobbs, NZ, Henley, SM, Ridgway, GR, Wild, EJ, Barker, RA, Scahill, RI, et al. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry
2010; 81: 756–63.
Domínguez, D JF, Egan, GF, Gray, MA, Poudel, GR, Churchyard, A, Chua, P, et al. Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 Month Longitudinal Data from the IMAGE-HD Study. PloS ONE
2013; 8: e74131.
Katz, R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx
2004; 1: 189–95.
Nelson, HE, Willison, J. National Adult Reading Test (NART): Test Manual. NFER Nelson, 1991.
Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord
1996; 11: 136–42.
Tabrizi, SJ, Langbehn, DR, Leavitt, BR, Roos, RA, Durr, A, Craufurd, D, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol
2009; 8: 791–801.
Stout, JC, Paulsen, JS, Queller, S, Solomon, AC, Whitlock, KB, Campbell, JC, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology
2011; 25: 1–14.
Smith, A. Symbol Digit Modality Test (SDMT): Manual (Revised).
Psychological Services, 1982.
Stroop, JR. Studies of interference in serial verbal reactions. J Exp Psychol
1935; 18: 643–62.
Georgiou-Karistianis, N, Poudel, GR, Domínguez, D JF, Langmaid, R, Gray, MA, Churchyard, A, et al. Functional and connectivity changes during working memory in Huntington's disease: 18 month longitudinal data from the IMAGE-HD study. Brain Cogn
2013; 83: 80–91.
Georgiou-Karistianis, N, Stout, JC, Domínguez, D J, Carron, SP, Ando, A, Churchyard, A, et al. Functional magnetic resonance imaging of working memory in Huntington's disease: cross-sectional data from the IMAGE-HD study. Hum Brain Mapp
2014; 35: 1847–64.
Poudel, GR, Stout, JC, Gray, MA, Domínguez, D JF, Salmon, L, Churchyard, A, et al. Functional changes during working memory in Huntington's disease: 30 month longitudinal data from the IMAGE-HD study. Brain Struct Funct
2015; 220: 501–12.
Gray, MA, Egan, GF, Ando, A, Churchyard, A, Chua, P, Stout, JC, et al. Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study. Exp Neurol
2013; 239: 218–28.
Grace, J, Mallory, PF. Frontal Systems Behavior Scale: Professional Manual.
Psychological Assessment Resources, 2001.
Watson, D, Wu, KD. Development and validation of the schedule of compulsions, obsessions, and pathological impulses (SCOPI). Assessment
2005; 12: 50–65.
Georgiou-Karistianis, N, Gray, MA, Domínguez, D JF, Dymowski, AR, Bohanna, I, Johnston, LA, et al. Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: the IMAGE-HD study. Neurobiol Dis
2013; 51: 82–92.
Zhang, Y, Brady, M, Smith, S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging
2001; 20: 45–57.
Patenaude, B, Smith, S, Kennedy, D, Jenkinson, M. Bayesian statistical models of shape and appearance for subcortical brain segmentation. NeuroImage
2011; 56: 907–22.
Moncrieff, J, Leo, J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med
2010; 40: 1409–22.
Penney, JB, Vonsattel, J-P, Macdonald, ME, Gusella, JF, Myers, RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol
1997; 41: 689–92.
StataCorp. Stata Statistical Software: Release 12. StataCorp LP, 2011.
Calamia, M, Markon, K, Tranel, D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. Clin Neuropsychol
2012; 26: 543–70.
Hobbs, NZ, Barnes, J, Frost, C, Henley, SMD, Wild, EJ, Macdonald, K, et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. Am J Neuroradiol
2010; 31: 1036–41.
Majid, DS, Aron, AR, Thompson, W, Sheldon, S, Hamza, S, Stoffers, D, et al. Basal ganglia atrophy in prodromal Huntington's disease is detectable over 1 year using automated segmentation. Mov Disord
2011; 26: 2544–51.
Tabrizi, SJ, Reilmann, R, Roos, RA, Durr, A, Leavitt, B, Owen, G, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol
2012; 11: 42–53.
Tabrizi, SJ, Scahill, RI, Owen, G, Durr, A, Leavitt, BR, Roos, RA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol
2013; 12: 637–49.
Reuter, M, Schmansky, NJ, Rosas, HD, Fischl, B. Within-subject template estimation for unbiased longitudinal image analysis. NeuroImage
2012; 61: 1402–18.
Magnotta, VA, Harris, G, Andreasen, NC, O'Leary, DS, Yuh, WTC, Heckel, D. Structural MR image processing using the BRAINS2 toolbox. Comput Med Imag Grap
2002; 26: 251–64.
Freeborough, PA, Fox, NC, Kitney, RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed
1997; 53: 15–25.
Rosas, HD, Tuch, DS, Hevelone, ND, Zaleta, AK, Vangel, M, Hersch, SM, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures. Mov Disord
2006; 21: 1317–25.
Douaud, G, Behrens, TE, Poupon, C, Cointepas, Y, Jbabdi, S, Gaura, V, et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. NeuroImage
2009; 46: 958–66.
Sánchez-Castañeda, C, Cherubini, A, Elifani, F, Peran, P, Orobello, S, Capelli, G, et al. Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp
2013; 34: 1625–35.
Sritharan, A, Egan, GF, Johnston, L, Horne, M, Bradshaw, JL, Bohanna, I, et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J Neurol Neurosurg Psychiatry
2010; 81: 257–62.
Vandenberghe, W, Demaerel, P, Dom, R, Maes, F. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. J Neurol
2009; 256: 109–14.
Myers, RH, Vonsattel, JP, Paskevich, PA, Kiely, DK, Stevens, TJ, Cupples, LA, et al. Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J Neuropathol Exp Neurol
1991; 50: 729–42.
Gómez-Tortosa, E, MacDonald, ME, Friend, JC, Taylor, SA, Weiler, LJ, Cupples, LA, et al. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol
2001; 49: 29–34.
Mandelli, ML, Savoiardo, M, Minati, L, Mariotti, C, Aquino, D, Erbetta, A, et al. Decreased diffusivity in the caudate nucleus of presymptomatic Huntington disease gene carriers: which explanation?
Am J Neuroradiol
2010; 31: 706–10.
Bartzokis, G, Lu, PH, Tishler, TA, Fong, SM, Oluwadara, B, Finn, JP, et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res
2007; 32: 1655–64.
Rosas, HD, Chen, YI, Doros, G, Salat, DH, Chen, NK, Kwong, KK, et al. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol
2012; 69: 887–93.
Tanis, KQ, Newton, SS, Duman, RS. Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development. CNS Neurol Disord Drug Targets
2007; 6: 151–60.
Hua, X, Hibar, DP, Ching, CR, Boyle, CP, Rajagopalan, P, Gutman, BA, et al. Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. NeuroImage
2013; 66: 648–61.